Docoh
Loading...

63 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2015 Q3
EX-10.3
PRPO Precipio Inc
15 Nov 15
Quarterly report
7:00pm
$ 300,000 (the “Purchase”). If the key (Two members of GAP leadership) people belonging to the GAP BU turn out to be avoiding to come to ADSTEC, both … balance) All contracts relating solely to the GAP BU Key GAP Leadership David Hild and Ben Nouri TRANSGENOMIC, INC. ADSTEC Corporation By: /s/ Paul
8-K
EX-99.1
PRPO Precipio Inc
29 Sep 13
Transgenomic Announces Executive Changes
8:00pm
and a Director, replacing Craig J. Tuttle, effective today. Mr. Kinnon brings over two decades of business and scientific leadership … experience covering clinical diagnostic, core life science research and applied markets, his appointment strengthens the executive leadership team
8-K
EX-99.1
PRPO Precipio Inc
29 May 03
Transgenomic Announces Changes In Management Responsibilities In Line with Evolving Business Segment Focus
8:00pm
an extensive business background along with strong organizational and leadership skills to the task of managing both business segments’ manufacturing … operations.” Regarding the consolidation of sales and marketing, and research and development leadership, D’Silva commented, “The managers within both of our
8-K
EX-99.1
PRPO Precipio Inc
3 Mar 21
Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors
4:30pm
force within the company’s leadership.” Dr. Douglas Fisher joined the company’s board in 2017 and assumed the role of Chairman in December 2019 … . During those years and under Doug’s leadership, the company completed the transition following its merger with Transgenomic; erased past liabilities
8-K
EX-99.1
PRPO Precipio Inc
15 Sep 11
Regulation FD Disclosure
8:00pm
space Molecular diagnostics alone $7BB, projected to grow to $58BB by 2026, or 15%/year 4 Source : G - 2 Reports Our Pathway to Market Leadership 5 … menu – License new markers – Acquire and integrate complementary businesses Leverage mutation detection sensitivity leadership to build and market
8-K
EX-99.1
ruq2m fsy
6 Oct 11
Regulation FD Disclosure
8:00pm
8-K
d6pmk1 5n
29 Sep 13
Transgenomic Announces Executive Changes
8:00pm
8-K
EX-99.1
dg348
5 Nov 13
Transgenomic Reports Third Quarter 2013 Financial Results
7:00pm
DEF 14A
3mcra
29 Apr 19
Definitive proxy
5:22pm
8-K
EX-99.1
lu5jvgvfyh3ie3b
4 Apr 06
Departure of Directors or Principal Officers
8:00pm
8-K
EX-99.1
4q86ja8zabkg111967
5 Jan 12
Transgenomic Announces $3 Million Convertible Note Financing
7:00pm
8-K
EX-99.1
k1u cj4xz65w87
14 Nov 06
Departure of Directors or Principal Officers
7:00pm
8-K
EX-99.1
3zghtovgaoa5tkw
17 Apr 07
Departure of Directors or Principal Officers
8:00pm
8-K
EX-99.1
yapt14nnbe k5xb
18 Mar 14
Dr. Michael A. Luther Joins Transgenomic’s Board of Directors
8:00pm
CORRESP
oftp giwzzdp
21 Jul 15
Correspondence with SEC
8:00pm
8-K
EX-99.1
5vwrgsyx
14 May 14
John D. Thompson Joins Transgenomic’s Board of Directors
8:00pm
8-K
EX-99.1
vcjqwtv4j6zzn7
16 Sep 12
Departure of Directors or Certain Officers
8:00pm
8-K
EX-99.1
egq3vdwebnalw0n58x5n
2 Feb 12
Transgenomic Announces $22.0 Million Private Placement Financing
7:00pm
8-K
EX-99.1
cpycu95zubl1
12 Mar 13
Transgenomic Secures $8.0 Million Credit Facility
8:00pm
8-K
EX-99.1
qfitni8a
24 Jan 13
Transgenomic Announces $8.3 Million Private Placement Financing
7:00pm